Michigan Spent $82M on Medicaid Contract With Little Oversight, Audit Finds

Key Takeaways

• $82M Medicaid contract lacked independent performance verification
• Monitoring plan unchanged for years despite contract modifications
• State failed to document oversight activities per procurement rules
• Audit recommends stricter oversight and documentation protocols

Summary

A Michigan state audit uncovered that the Department of Health and Human Services failed to adequately monitor an $82 million contract with Prime Therapeutics State Government Solutions, a pharmacy‑benefits manager for Medicaid. Over a seven‑and‑a‑half‑year period, oversight relied heavily on the contractor’s self‑reported data, with little independent verification or documentation. Auditors flagged missing performance reviews, outdated monitoring plans, and inconsistent enforcement of penalties. The report recommends a comprehensive overhaul of the department’s oversight procedures.

Pulse Analysis

Medicaid’s reliance on private pharmacy‑benefits managers (PBMs) has grown as states seek cost efficiencies, yet the Michigan audit reveals how that model can backfire without rigorous supervision. PBMs like Prime Therapeutics handle claim processing and rebate negotiations, functions that directly affect drug pricing and patient access. When a state’s health agency leans on self‑reported metrics instead of conducting its own audits, it creates blind spots that can mask overcharges, service gaps, or fraud, undermining the intended savings of the partnership.

The audit’s findings raise red flags for Michigan’s fiscal stewardship. By allowing a high‑risk contract to operate with an outdated monitoring plan, the Department of Health and Human Services not only violated state procurement rules but also missed opportunities to intervene when performance slipped. Lawmakers, such as Rep. Jamie Thompson, argue that this negligence fuels public distrust and jeopardizes the quality of care for vulnerable Medicaid families. The department’s partial disagreement with the audit underscores a broader cultural issue: a reluctance to adopt transparent, data‑driven oversight mechanisms that could preempt financial missteps.

Nationally, the Michigan case serves as a cautionary tale for other states expanding PBM contracts. As federal and state budgets tighten, the pressure to demonstrate cost‑effectiveness intensifies, making robust contract management essential. Recommendations from the audit—updating monitoring frameworks, instituting independent verification, and enforcing penalty clauses—align with best practices endorsed by the Government Accountability Office. Implementing these steps can safeguard taxpayer dollars, improve drug‑benefit outcomes, and restore confidence in public‑sector procurement processes.